In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 35226528.
- Also identified by DOI 10.7326/J22-0003.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Kanie T, Mizuno A, Takaoka Y, et al. <b>Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.</b> Cochrane Database Syst Rev. 2021;10:CD013650. 34693515.
Medical subject headings
- Cardiovascular Diseases
- Diabetes Mellitus, Type 2
- Dipeptidyl-Peptidase IV Inhibitors
- Sodium-Glucose Transporter 2 Inhibitors